In all, 100 unrelated donor bone marrow transplantations (UD-BMT) were performed in our institute between October 1993 and January 2003. Of 93 evaluable patients, 73 patients had hematological malignancy, 13 had nonmalignancy and seven had lymphoproliferative disease. The estimated 9-year event-free survival (EFS) rate was 57.175.5% in all patients. In the following analyses of the patients with hematological malignancy, the standard group had significantly better EFS than the high-risk group (61.577.0 vs 35.679.7%, P ¼ 0.02), and the EFS rate of the tacrolimus (FK-506) þ methotrexate (MTX)7methylprednisolone prophylactic group for graft-versus-host disease was superior to that of the FK-506 without MTX group (75.778.0 vs 55.877.6%, P ¼ 0.02). When we compared the EFS rates of the FK506 þ MTX7methylprednisolone (mPSL) group and the HLA-matched related donor BMT group in our institute, these were almost similar (75.778.1 vs 68.47 9.3%). Therefore, UD-BMT using FK-506 þ MTX7 mPSL is a safe and useful method for children with hematological malignancy who require allogeneic BMT. In general, the rates of severe graft-versus-host disease (GVHD) and transplant-related mortality in UD-BMT are higher than in HLA-matched related donor BMT. Of the problems in UD-BMT, reducing the incidence of severe GVHD is the most important for successful UD-BMT. To reduce severe GVHD, JMDP introduced a high-resolution technique for the analysis of HLA typing in 1997 following the results of JMDP research that mismatched HLA class I alleles between donors and recipients induces severe GVHD.
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Bone marrow transplantation (BMT) is frequently considered as a curative treatment for children with serious hematological disorders. However, about 75% of patients lack HLA-identical family donors. The unrelated bone marrow donor program started in 1991 in Japan and more than 4000 unrelated donor (UD)-BMTs were performed up to 2003 by the Japanese Marrow Donor Program (JMDP). In general, the rates of severe graft-versus-host disease (GVHD) and transplant-related mortality in UD-BMT are higher than in HLA-matched related donor BMT. Of the problems in UD-BMT, reducing the incidence of severe GVHD is the most important for successful UD-BMT. To reduce severe GVHD, JMDP introduced a high-resolution technique for the analysis of HLA typing in 1997 following the results of JMDP research that mismatched HLA class I alleles between donors and recipients induces severe GVHD. 1 In our institute, we performed 104 UD-BMTs for 100 patients between October 1993 and January 2003. In order to reduce severe GVHD, we used tacrolimus (FK-506) for prophylaxis of GVHD, which demonstrated immunosuppressive effects 100-fold greater than cyclosporin A (CsA) in vitro. 2 However, we tried to control the plasma concentration of FK-506 and its adverse effects at an early stage. We then used a low initial dose of FK-506 to reduce its toxicity and added a minidose of methotrexate (MTX) to reduce GVHD, which has resulted in the successful decrease of the toxicities of FK-506 and severe GVHD in UD-BMT.
Patients and methods

Patients
Between October 1993 and January 2003, 100 patients received 104 instances of UD-BMT in our institute. Of these, four patients received two UD-BMTs because of relapse of the original disease or graft rejection. Four patients underwent autologous stem cell transplantation and two underwent cord blood transplantation before receiving UD-BMT. We excluded second UD-BMT and seven patients who received reduced-intensity BMT from following analyses. The estimated 93 patients' characteristics are shown in Table 1 . Underlying diseases were acute lymphoblastic leukemia (ALL) and leukemic change of non-Hodgkin's lymphoma (NHL) in 38, acute myeloid leukemia (AML) in 22, myelodysplastic syndrome (MDS) in seven and chronic myeloid leukemia (CML) in six. Nonhematological malignant diseases were Epstein-Barr virus-associated lymphoproliferative disease (LPD) including hemophagocytic syndrome (HPS) in seven, bone marrow failure (aplastic anemia, congenital thrombocytopenia, pure red cell aplasia, congenital dyserythropoietic anemia) in 10, immunodeficiency in two and metabolic disease in one. In hematological malignancy, the status at BMT of first and second complete remission of acute leukemia, first chronic phase of CML and refractory anemia in MDS were defined as the standard-risk group and other statuses comprised the high-risk group. In all, 51 patients were included in the standard-risk group and 22 in the high-risk group.
All patients (or their parents) included in this study signed informed consents approved by the Institute Review Board of Osaka Medical Center and Research Institute for Maternal and Child Health.
Methods of BMT
In principal, conditioning regimens consisted of 12 Gy of total body irradiation (TBI) þ 140-210 mg/m 2 of melphalan (L-PAM) or 300 mg/m 2 of thiotepa or 120 mg/kg of cyclophosphamide (CPM) with or without other agents for hematological malignancy and LPD/HPS, TBI (10 Gy) þ CPM (120 mg/kg) with or without other agents for bone marrow failure, and busulfan (16 mg/kg) þ CPM (200 mg/kg) with or without other agents for immunodeficiency and metabolic disease. There were three prophylactic methods against GVHD. Before 1997, FK-506 with or without methylprednisolone (mPSL) was used in 40 patients, and CsA and MTX with or without mPSL in 10. After February 1997, we started using FK-506 and MTX with mPSL for UD-BMT of HLA-mismatched pairs, and after July 1999, FK506 þ MTX was used for HLA-matched pairs. The starting dose of FK-506 was 0.05-0.1 mg/kg/day in the FK-5067mPSL group and 0.02-0.03 mg/kg/day in the FK-506 þ MTX7mPSL group. The dose of MTX was 7.5 mg/m 2 and it was administered on days 1, 3 and 6 after BMT. We set up the optimal plasma concentration of FK-506 as 10-15 ng/ml through this period.
In hematological malignancy, the age, gender, underlying disease and status of disease were not different between FK-506 þ MTX7mPSL group and the other prophylactic group. Melphalan was commonly used as conditioning regimen in the other prophylactic group. In genotypical discrepancy of HLA, the incidence of class I allele mismatch is almost same in both groups, although the number of class II mismatched transplantations was 11 in FK-506 þ MTX7mPSL group, with none in the other prophylactic group.
Supportive care
Growth factor administration, isolation, and antibacterial, antifungal and antiviral prophylaxis were performed according to our institutional protocols. Briefly, all patients were under laminar air flow protection and received G-CSF intravenously from day 5 until the WBC reached 5 Â 10 9 /l. All blood products were filtered and irradiated to 1500 cGy, and transfused to maintain hemoglobin levels of 8.0 g/dl and platelets count of 20 Â 10 9 /l. If both donor and recipient were serologically negative for CMV, we used CMV-negative blood products only. Acyclovir was administered from day À7 until day 30 for prophylaxis of herpes simplex. For prophylaxis of CMV infection in serologically CMV-positive donor and recipient, ganciclovir (5.0 mg/kg twice a day) was administered from day À8 until day À1 and the dose of 7.5 mg was administered three times a week after engraftment until day þ 100. Trimethoprim/sulfamethoxazole was started after engraftment for prophylaxis of Pneumocystis carinii.
Statistical analysis
Overall survival and event-free survival (EPS) curves were calculated using the Kaplan-Meier method and the logrank test was used for comparison of curves. The variables of each group were compared using the w 2 test.
Results
Overall survival and EFS rates
The estimated 9-year overall survival and EFS rates in all patients were 59.375.3 and 57.175.5%, respectively. According to the underlying disease, the EFS rate of hematological malignancy was 55.776.0%, nonmalignancy (bone marrow failure, immunodeficiency and metabolic disorder) was 59.3714.3% and LPD/HPS was 85.7713.2% ( Figure 1 ). In hematological malignancies, the EFS rate of the standard-risk group tended to be superior to that of the high-risk group (61.577.0 vs 40.4710.6%, P ¼ 0.06). The high-risk group included seven patients from the FK-506 þ MTX7mPSL group and 15 from the other prophylactic group. Of these, 11 patients died, eight of transplant-related toxicity (one in FK-506 þ MTX7mPSL group and seven in the other prophylactic group) and three of original disease.
Incidence of GVHD Table 2 shows the incidence of GVHD in hematological malignancy. Acute GVHD was observed in 76% of patients. The incidence of acute GVHD greater than grade II was 60.6% and greater than grade III was 35.2%. In all, 55 patients were evaluable for chronic GVHD. A total of 50 patients suffered chronic GVHD, and of these, 14 were extensive type. When we compared three different GVHD prophylactic groups in hematological malignancy, the incidence of severe acute GVHD (Xgrade III) and extensive chronic GVHD were significantly lower in the FK-506 þ MTX7mPSL group (acute GVHD: P ¼ 0.05; and chronic GVHD: P ¼ 0.02). In patients transplanted from genotypically HLA-mismatched donors, severe acute GVHD occurred in three of 15 patients (one of 4 in the class I mismatched group and two of 11 in the class II Unrelated bone marrow transplantation for children K Yumura-Yagi et al Table 1 Patients' characteristics 
Causes of failure
Of three patients who suffered graft rejection, two had received UD-BMT from class I HLA-mismatched donors.
All three patients showed recovery of autologous bone marrow. One patient with CML relapsed and died of GVHD after second UD-BMT. The other patient with MDS is doing well after second transplantation. The remainder with Hurler's syndrome is alive with original disease. In hematologic malignancy, the causes of failure are shown in Table 3 . Of 30 patients in the FK-506 þ MTX7mPSL group, one patient died of acute GVHD and two of veno-occlusive disease within 100 days after BMT; in the other prophylactic group, 15 of 52 patients died of transplant-related complications. We previously reported precisely adverse effects in 40 patients in the FK-5067mPSL group. Briefly, administration of FK 506 was stopped in 22 of 40 patients because of renal dysfunction or neurological toxicity. 3 Of 22 patients, 15 suffered severe acute GVHD. In particular, the incidence of acute GVHD as a cause of failure was low in the FK-506 þ MTX7mPSL group. Infection without GVHD Other group 55.8±7.6%
P=0.017
(day) Figure 2 Comparison of EFS curves according to different methods of GVHD in patients with hematological malignant disease. EFS rate in the FK-506 þ MTX7mPSL group is better than that of the FK-506 without MTX group (P ¼ 0.02).
Unrelated bone marrow transplantation for children K Yumura-Yagi et al was seen in two patients. One patient suffered fungal infection and another developed interstitial pneumonia of unknown origin. CMV infection was observed in three patients accompanied by severe GVHD. At 4100 days after UD-BMT, eight patients in the FK-506 þ MTX7mPSL group failed and out of them, six suffered relapse of the original disease. In the other prophylactic groups, relapse was observed in four patients, transplant-related death in nine and rejection in two. GVHD-related deaths were also fewer in the FK-506 þ MTX7mPSL group than in the other prophylactic groups as seen in the early duration after BMT.
Comparison between RD-BMT and UD-BMT
Between February 1997 and January 2003, 26 patients with hematological malignancies underwent BMT from HLAidentical related donors (RD-BMT) in our institute. The characteristics of these patients are shown in Table 1 . When we compared RD-BMT and FK-506 þ MTX7mPSL group of UD-BMT in hematologic malignancies, there was no significant difference in age, gender, status of underlying diseases and conditioning regimen. For GVHD prophylaxis, CsA was usually used in the RBMT group. The estimated 5-year EFS rates were similar in both groups, that is, 75.778.0% in the UD-BMT group and 68.479.3% in RD-BMT, respectively ( Figure 3 ). When patients were separated into standard-risk and high-risk groups, there was also no significant difference in EFS between the RD-BMT and the UD-BMT groups (data not shown).
Discussion
BMT is a powerful treatment for patients with hematological disorders. Recent advances in medicine have made it possible to transplant using sources of stem cells other than bone marrow, and donors other than HLA-identical donors. However, BMT from HLA-identical donors is the most established of various methods of stem cell transplantation. Generally, only 25% of patients who require BMT have suitable family donors. Therefore, the unrelated bone marrow donor program is very important for these patients. In Japan, more than 4000 UD-BMTs were performed using JMDP donors up to 2003. The reported EFS rates of UD-BMT in children vary according to underlying diseases and status of leukemia. In the Fred Hutchinson Cancer Research Center, the diseasefree survival rates were 75% for patients with CML, 47 and 20% for ALL in first/second remissions and in relapse/third remission, 48 and 46% for AML in remission and in advanced disease. 4 In the Italian group (AIEOP and GITMO), it has been reported that the rate of diseasefree survival at 3 years was 37% for patients with ALL, 38% for AML and MDS, 59% for birth defects and 51% for CML. 5 The National Marrow Donor Program has reported that the 5-year overall survival rate and relapsefree survival were 38 and 36%, respectively, in children with ALL in second remission. 6 For aplastic anemia, JMDP reported that the 5-year EFS rate in recipients less than 20 years old was 69%. 7 In this study, the EFS rates in hematological malignancy were 61.577.0% in the standard-risk group, 35.679.7% in the high-risk group and 59.9% in patients with bone marrow failure and immunodeficiency, respectively. Our results seem to be not much better than those in previous reports. However, in the FK-506 þ MTX group, superior EFS was observed in hematological malignancy. In the FK-506 without MTX group, high transplant-related mortality with severe GVHD was observed in hematological malignancy. Also in the nonmalignancy group, two of five patients in the FK-506 without MTX group died of cGVHD at 8 and 43 months from BMT. Table 3 Causes of failure (hematological malignancy only)
GVHD prophylaxis
Others FK-506+MTX 7mPSL
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CsA7MTX 7mPSL
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In UD-BMT, reduction of severe GVHD plays an important role in successful outcome. Severe GVHD is induced by a mismatch of histocompatibility between the donor and patient. Therefore, the incidence of GVHD is higher in UD-BMT than in RD-BMT from serologically HLA-identical donors because of differences in the HLA genotype between donors and patients in UD-BMT. JMDP showed that the incidence of severe GVHD is crosslinked to a mismatch of HLA alleles, and grade III-IV GVHD occurred in more than 20% of mismatched class I allele pairs and more than 30% of class I and class II allele mismatched pairs. 8 Based on these findings, JMDP has introduced a high-resolution technique for HLA analysis to detect suitable HLA-matched donors. JMDP reports in aplastic anemia also showed that a mismatch of HLA alleles had the most significant influence on survival. 7 The methods of prophylaxis for GVHD vary, but the combination of short-term MTX and CsA is common in HLA-identical related donor BMT. FK-506, whose immunosuppressive potency is 50-to 200-fold greater than that of CsA in vitro, was developed in Japan 2 and clinical trials were introduced in the late 1980s. Phase II and phase III studies of HLA-identical BMT recipients revealed that a parental dose of 0.05 mg/kg was effective for acute and chronic GVHD and prophylaxis of GVHD and low incidence of grade II-IV GVHD in the FK-506 þ MTX group compared to the CsA and MTX groups. 9, 10 Although FK-506 is useful in the prophylaxis and treatment of GVHD, many adverse effects have been reported such as renal dysfunction, encephalopathy and thrombotic microangiopathy. [11] [12] [13] We also attempted to control the concentration of FK-506 in plasma and stopped the administration of FK-506 because of high plasma concentration and/or adverse effects in early cases. We then reduced the starting dose of FK-506 from 0.05 to 0.02-0.03 mg/kg/day and adding a low dose of MTX (7.5 mg/m 2 ) for prophylaxis against GVHD, which resulted in the reduction of severe acute GVHD and extensive chronic GVHD. Although this study included five patients with HLA class I allele mismatched donors and 14 patients with HLA class II allele mismatched donors in the FK-506 þ MTX7mPSL group, only one patient suffered grade IV GVHD and two patients developed grade III GVHD. Also in seven patients with BM failure in the FK-506 þ MTX7mPSL group, only one developed grade III GVHD, although this group included two each of class I and class II allele HLA-mismatched pairs. The efficacy of the method of combining the minidose of MTX and the low initial dose of FK-506 was reported by the MD Anderson Cancer Center group, 14 and recently, the Dana-Farber Cancer Institute group has also demonstrated efficacy of this combination with added sirolimua. 15 In these reports, 5 mg/m 2 MTX was given on days 1, 3, 5 and 11. We omitted MTX on day 11 because our previous analysis showed rapid hematopoietic reconstitution using this method of GVHD prophylaxis 3 and we speculated that the risk of infection due to neutropenia might be reduced with this method. The MD Anderson group also demonstrated that 67% of patients were not administered MTX on day 11 because of mucosal injury. To determine the most suitable method for prophylaxis against GVHD in UD-BMT, a further controlled study may be required.
To reduce transplant-related death, the preparative regimen is also important apart from GVHD prevention. Recent reports show that reduced-intensity stem cell transplantation (RIST) is able to decrease the toxicity of the preconditioning regimen. 16 In children, RIST will result in decreased short-and long-term adverse effects, and several trials of RIST have started. 17, 18 We performed RIST from UD for eight patients in the same period of this study. Engraftment was observed in all eight patients. Five patients with aplastic anemia or immunodeficiency had lower toxicity and all are doing well, whereas three patients with leukemia, who underwent UD-BMT for relapse after SCT or fourth remission, died of a subsequent relapse in two and GVHD in one after UD-BMT. The indication for RIST in children will be a future consideration.
We compared the results of UD-BMT and RD-BMT in hematological malignancy during same period at our institute, and showed about 70% EFS rate in both groups. The report from the St Jude Children's Hospital group showed similar results to our study as a single institute's experience with low incidence of GVHD in UD-BMT. They used T-cell depletion for GVHD prophylaxis. 19 Our findings revealed that UD-BMT using FK-506 and MTX7mPSL for prophylaxis of GVHD is as safe and useful as BMT from HLA-identical family donors in children with hematological malignancy.
